The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boyaka, P. N.
Right arrow Articles by McGhee, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyaka, P. N.
Right arrow Articles by McGhee, J. R.
The Journal of Immunology, 2003, 170: 5636-5643.
Copyright © 2003 by The American Association of Immunologists

Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen1

Prosper N. Boyaka2,*, Angela Tafaro*, Romy Fischer*, Stephen H. Leppla{dagger}, Kohtaro Fujihashi* and Jerry R. McGhee2,*

* Departments of Microbiology and Oral Biology, Immunobiology Vaccine Center, University of Alabama, Birmingham, AL 35294; and {dagger} Microbial Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

Mucosal, but not parenteral, immunization induces immune responses in both systemic and secretory immune compartments. Thus, despite the reports that Abs to the protective Ag of anthrax (PA) have both anti-toxin and anti-spore activities, a vaccine administered parenterally, such as the aluminum-adsorbed anthrax vaccine, will most likely not induce the needed mucosal immunity to efficiently protect the initial site of infection with inhaled anthrax spores. We therefore took a nasal anthrax vaccine approach to attempt to induce protective immunity both at mucosal surfaces and in the peripheral immune compartment. Mice nasally immunized with recombinant PA (rPA) and cholera toxin (CT) as mucosal adjuvant developed high plasma PA-specific IgG Ab responses. Plasma IgA Abs as well as secretory IgA anti-PA Abs in saliva, nasal washes, and fecal extracts were also induced when a higher dose of rPA was used. The anti-PA IgG subclass responses to nasal rPA plus CT consisted of IgG1 and IgG2b Abs. A more balanced profile of IgG subclasses with IgG1, IgG2a, and IgG2b Abs was seen when rPA was given with a CpG oligodeoxynucleotide as adjuvant, suggesting a role for the adjuvants in the nasal rPA-induced immunity. The PA-specific CD4+ T cells from mice nasally immunized with rPA and CT as adjuvant secreted low levels of CD4+ Th1-type cytokines in vitro, but exhibited elevated IL-4, IL-5, IL-6, and IL-10 responses. The functional significance of the anti-PA Ab responses was established in an in vitro macrophage toxicity assay in which both plasma and mucosal secretions neutralized the lethal effects of Bacillus anthracis toxin.




This article has been cited by other articles:


Home page
 CVIHome page
Q. Xu and M. Zeng
Detoxified Lethal Toxin as a Potential Mucosal Vaccine against Anthrax
Clin. Vaccine Immunol., April 1, 2008; 15(4): 612 - 616.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
H. F. Staats, S. M. Alam, R. M. Scearce, S. M. Kirwan, J. X. Zhang, W. M. Gwinn, and B. F. Haynes
In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity
Infect. Immun., November 1, 2007; 75(11): 5443 - 5452.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. U. Bielinska, K. W. Janczak, J. J. Landers, P. Makidon, L. E. Sower, J. W. Peterson, and J. R. Baker Jr.
Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects against Bacillus anthracis Spore Challenge
Infect. Immun., August 1, 2007; 75(8): 4020 - 4029.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Duverger, R. J. Jackson, F. W. van Ginkel, R. Fischer, A. Tafaro, S. H. Leppla, K. Fujihashi, H. Kiyono, J. R. McGhee, and P. N. Boyaka
Bacillus anthracis Edema Toxin Acts as an Adjuvant for Mucosal Immune Responses to Nasally Administered Vaccine Antigens
J. Immunol., February 1, 2006; 176(3): 1776 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. Aloni-Grinstein, O. Gat, Z. Altboum, B. Velan, S. Cohen, and A. Shafferman
Oral Spore Vaccine Based on Live Attenuated Nontoxinogenic Bacillus anthracis Expressing Recombinant Mutant Protective Antigen
Infect. Immun., July 1, 2005; 73(7): 4043 - 4053.
[Abstract] [Full Text] [PDF]

Home page
 Microbiol. Mol. Biol. Rev.Home page
A. J. Phipps, C. Premanandan, R. E. Barnewall, and M. D. Lairmore
Rabbit and Nonhuman Primate Models of Toxin-Targeting Human Anthrax Vaccines
Microbiol. Mol. Biol. Rev., December 1, 2004; 68(4): 617 - 629.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Hermanson, V. Whitlow, S. Parker, K. Tonsky, D. Rusalov, M. Ferrari, P. Lalor, M. Komai, R. Mere, M. Bell, et al.
A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores
PNAS, September 14, 2004; 101(37): 13601 - 13606.
[Abstract] [Full Text] [PDF]

Home page
 Microbiol. Mol. Biol. Rev.Home page
H. Barth, K. Aktories, M. R. Popoff, and B. G. Stiles
Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins
Microbiol. Mol. Biol. Rev., September 1, 2004; 68(3): 373 - 402.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.